Repligen Corporation (NASDAQ:RGEN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Repligen Corporation (NASDAQ:RGEN) has earned an average rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $164.6429.

A number of equities research analysts have weighed in on RGEN shares. HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Wolfe Research started coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target for the company. Canaccord Genuity Group cut their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, HSBC reduced their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd.

Institutional Trading of Repligen

A number of hedge funds have recently bought and sold shares of RGEN. United Capital Financial Advisors LLC purchased a new stake in Repligen during the third quarter valued at about $368,387,000. Opti Capital Management LP purchased a new stake in Repligen during the fourth quarter valued at about $2,399,209,000. Maverick Capital Ltd. purchased a new stake in Repligen during the first quarter valued at about $178,946,000. Wasatch Advisors LP purchased a new stake in Repligen during the first quarter valued at about $146,513,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Repligen during the fourth quarter valued at about $199,176,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $145.23 on Friday. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.19 billion, a price-to-earnings ratio of 161.37, a PEG ratio of 2.67 and a beta of 1.09. The firm has a 50-day moving average of $122.54 and a two-hundred day moving average of $135.46.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period in the prior year, the company earned $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts expect that Repligen will post 1.99 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.